- Home
- PKST vs CRVS Comparison
PKST vs CRVS Comparison
Compare PKST & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKST
- CRVS
- Stock Information
- Founded
- PKST 2008
- CRVS 2014
- Country
- PKST United States
- CRVS United States
- Employees
- PKST N/A
- CRVS N/A
- Industry
- PKST Real Estate Investment Trusts
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PKST Real Estate
- CRVS Health Care
- Exchange
- PKST Nasdaq
- CRVS Nasdaq
- Market Cap
- PKST 478.3M
- CRVS 459.0M
- IPO Year
- PKST N/A
- CRVS 2016
- Fundamental
- Price
- PKST $13.28
- CRVS $7.62
- Analyst Decision
- PKST Strong Buy
- CRVS Strong Buy
- Analyst Count
- PKST 2
- CRVS 4
- Target Price
- PKST $17.50
- CRVS $13.75
- AVG Volume (30 Days)
- PKST 182.2K
- CRVS 1.1M
- Earning Date
- PKST 11-05-2025
- CRVS 11-04-2025
- Dividend Yield
- PKST 2.96%
- CRVS N/A
- EPS Growth
- PKST N/A
- CRVS N/A
- EPS
- PKST N/A
- CRVS N/A
- Revenue
- PKST $223,891,000.00
- CRVS N/A
- Revenue This Year
- PKST N/A
- CRVS N/A
- Revenue Next Year
- PKST N/A
- CRVS N/A
- P/E Ratio
- PKST N/A
- CRVS N/A
- Revenue Growth
- PKST N/A
- CRVS N/A
- 52 Week Low
- PKST $10.14
- CRVS $2.54
- 52 Week High
- PKST $14.59
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PKST 51.20
- CRVS 55.35
- Support Level
- PKST $12.45
- CRVS $7.50
- Resistance Level
- PKST $14.27
- CRVS $8.44
- Average True Range (ATR)
- PKST 0.46
- CRVS 0.52
- MACD
- PKST 0.01
- CRVS -0.03
- Stochastic Oscillator
- PKST 56.78
- CRVS 46.01
About PKST Peakstone Realty Trust
Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).